Filing Details
- Accession Number:
- 0000950170-23-033841
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-07-21 16:30:27
- Reporting Period:
- 2023-07-19
- Accepted Time:
- 2023-07-21 16:30:27
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1521036 | Lantheus Holdings Inc. | LNTH | In Vitro & In Vivo Diagnostic Substances (2835) | 352318913 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1876279 | Andrea Sabens | C/O Lantheus Holdings, Inc. 201 Burlington Road, South Bldg Bedford MA 01730 | Chief Accounting Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2023-07-19 | 1,752 | $90.87 | 59,767 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- The Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions in compliance with Rule 10b5-1. The transactions reported in this Form 4 were effected in compliance with Rule 10b5-1 to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4.